# Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct05689853/  
OnCo record `nct05689853` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AK119 in advanced solid tumours, run by Akeso, now recruiting.

## Summary

Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT05689853 by Akeso, with 87 participants planned, started 2023-04-14 and due to reach its primary completion in 2026-12. Interventions recorded: AK119 and AK112.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05689853
- Phase: 1/2
- Setting: An Open-label, Multicenter, Phase Ib/II Study to Evaluate the Safety, Tolerability and Antitumor Activity of AK119 in Combination With AK112 in Patients With Advanced Solid Tumors
- Sponsor: Akeso
- Enrolled: 87

## Sources

- ClinicalTrials.gov NCT05689853: https://clinicaltrials.gov/study/NCT05689853

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [AK119](https://onco.cc/drugs/ak119/)
- companies: [Akeso](https://onco.cc/companies/akeso/)

---
JSON: https://onco.cc/api/v1/entities/nct05689853.json